 |
PDBsum entry 2aa5
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transcription
|
PDB id
|
|
|
|
2aa5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transcription
|
 |
|
Title:
|
 |
Mineralocorticoid receptor with bound progesterone
|
|
Structure:
|
 |
Mineralocorticoid receptor. Chain: a, b. Fragment: ligand binding domain. Synonym: mr. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: nr3c2, mcr, mlr. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008.
|
|
Resolution:
|
 |
|
2.20Å
|
R-factor:
|
0.220
|
R-free:
|
0.264
|
|
|
Authors:
|
 |
R.K.Bledsoe,K.P.Madauss,J.A.Holt,C.J.Apolito,M.H.Lambert,K.H.Pearce, T.B.Stanley,E.L.Stewart,R.P.Trump,T.M.Willson,S.P.Williams
|
Key ref:
|
 |
R.K.Bledsoe
et al.
(2005).
A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor.
J Biol Chem,
280,
31283-31293.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
13-Jul-05
|
Release date:
|
26-Jul-05
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P08235
(MCR_HUMAN) -
Mineralocorticoid receptor from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
984 a.a.
255 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
280:31283-31293
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor.
|
|
R.K.Bledsoe,
K.P.Madauss,
J.A.Holt,
C.J.Apolito,
M.H.Lambert,
K.H.Pearce,
T.B.Stanley,
E.L.Stewart,
R.P.Trump,
T.M.Willson,
S.P.Williams.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Ligand binding is the first step in hormone regulation of mineralocorticoid
receptor (MR) activity. Here, we report multiple crystal structures of MR
(NR3C2) bound to both agonist and antagonists. These structures combined with
mutagenesis studies reveal that maximal receptor activation involves an
intricate ligand-mediated hydrogen bond network with Asn770 which serves dual
roles: stabilization of the loop preceding the C-terminal activation function-2
helix and direct contact with the hormone ligand. In addition, most activating
ligands hydrogen bond to Thr945 on helix 10. Structural characterization of the
naturally occurring S810L mutant explains how stabilization of a helix 3/helix 5
interaction can circumvent the requirement for this hydrogen bond network. Taken
together, these results explain the potency of MR activation by aldosterone, the
weak activation induced by progesterone and the antihypertensive agent
spironolactone, and the binding selectivity of cortisol over cortisone.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
FIG. 3. Crystal structure of MR LBD bound to aldosterone
and progesterone. A, the overall fold of MR is very similar to
the other steroid receptors. B, helix 3 (magenta) residues
Asn770 and Ser767 form hydrogen bonds (yellow dashed lines) with
the loop (green) residue Glu955 preceding the AF-2 (red). Thr945
present on helix 10 (orange) plays a key role in receptor
activation by hydrogen bonding to the C-20 carbonyl and C-21
hydroxyl of aldosterone (yellow). C, close-up view of
MR-aldosterone hydrogen bond network. The 18-OH is positioned
for hydrogen bonding (yellow dashed lines) with the Asn770
carbonyl, whereas the Asn770 amide remains in position for
hydrogen bonding to the C-21 OH of aldosterone and Glu955, which
lies in the loop preceding the AF-2. Thr945, present on helix
10, forms a pair of hydrogen bonds with the C-20 and C-21
substituents of aldosterone. Cysteine 942 is in position to
interact with the 18-OH group to give aldosterone three
potential hydrogen bonds to helix 10. D, progesterone makes no
hydrogen bonds to Asn770. Multiple orientations of the Thr945
side chain hydroxyl were observed (A and B) in both
noncrystallographically related molecules. When the Thr945 side
chain hydroxyl is in the B position (green), the distance (black
dashed line) to the progesterone C-20 carbonyl makes hydrogen
bonding between the ligand and Thr945 unlikely.
|
 |
Figure 5.
FIG. 5. Close-up views of the MR C808S/S810L mutant bound
to progesterone, cortisone, and spironolactone. A, an overlay of
progesterone (yellow) in MR C808S (cyan) and progesterone (pink)
in MR C808S/S810L (pink) binding pockets indicates that the
S810L mutation has no measurable effect on ligand position or
orientation. Hydrogen bonding networks (yellow dashed lines) are
indicated. Van der Waals interactions are indicated by black
dashed lines. Multiple orientations of the Thr945 side chain
hydroxyl were observed (A and B) in both noncrystallographically
related molecules. B, the C-11 carbonyl of cortisone (blue) does
not interact with MR C808S/S810L (orange) residue Asn770 and is
2.9
Å away from the backbone carbonyl of Leu769. C, the
lactone keto group of spironolactone (white) is 3.7
Å away from Asn770 in MR C808S/S810L (magenta), suggesting
a weakened potential for hydrogen bonding to Asn770. Again,
multiple orientations of the Thr945 side chain hydroxyl were
observed (A and B) in both noncrystallographically related
molecules. Similar to that observed with progesterone, the
distance from the hydroxyl of Thr945 to the lactone keto moiety
of spironolactone differs depending upon the orientation of this
residue. The weak interaction of spironolactone with both Asn770
and Thr945 is probably the basis for the antagonism observed
with this steroid.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2005,
280,
31283-31293)
copyright 2005.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.J.Kerrigan,
Q.Xie,
R.S.Ames,
and
Q.Lu
(2011).
Production of protein complexes via co-expression.
|
| |
Protein Expr Purif,
75,
1.
|
 |
|
|
|
|
 |
A.S.Veleiro,
L.D.Alvarez,
S.L.Eduardo,
and
G.Burton
(2010).
Structure of the glucocorticoid receptor, a flexible protein that can adapt to different ligands.
|
| |
ChemMedChem,
5,
649-659.
|
 |
|
|
|
|
 |
L.Jin,
and
Y.Li
(2010).
Structural and functional insights into nuclear receptor signaling.
|
| |
Adv Drug Deliv Rev,
62,
1218-1226.
|
 |
|
|
|
|
 |
P.Huang,
V.Chandra,
and
F.Rastinejad
(2010).
Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.
|
| |
Annu Rev Physiol,
72,
247-272.
|
 |
|
|
|
|
 |
R.Goyanka,
S.Das,
H.H.Samuels,
and
T.Cardozo
(2010).
Nuclear receptor engineering based on novel structure activity relationships revealed by farnesyl pyrophosphate.
|
| |
Protein Eng Des Sel,
23,
809-815.
|
 |
|
|
|
|
 |
C.D.Clyne,
C.Y.Chang,
R.Safi,
P.J.Fuller,
D.P.McDonnell,
and
M.J.Young
(2009).
Purification and characterization of recombinant human mineralocorticoid receptor.
|
| |
Mol Cell Endocrinol,
302,
81-85.
|
 |
|
|
|
|
 |
H.Fan,
J.J.Irwin,
B.M.Webb,
G.Klebe,
B.K.Shoichet,
and
A.Sali
(2009).
Molecular docking screens using comparative models of proteins.
|
| |
J Chem Inf Model,
49,
2512-2527.
|
 |
|
|
|
|
 |
J.Zhang,
and
D.S.Geller
(2008).
Helix 3-helix 5 interactions in steroid hormone receptor function.
|
| |
J Steroid Biochem Mol Biol,
109,
279-285.
|
 |
|
|
|
|
 |
M.Schubert,
F.Brunet,
M.Paris,
S.Bertrand,
G.Benoit,
and
V.Laudet
(2008).
Nuclear hormone receptor signaling in amphioxus.
|
| |
Dev Genes Evol,
218,
651-665.
|
 |
|
|
|
|
 |
N.Yoshimoto,
Y.Inaba,
S.Yamada,
M.Makishima,
M.Shimizu,
and
K.Yamamoto
(2008).
2-Methylene 19-nor-25-dehydro-1alpha-hydroxyvitamin D3 26,23-lactones: synthesis, biological activities and molecular basis of passive antagonism.
|
| |
Bioorg Med Chem,
16,
457-473.
|
 |
|
|
|
|
 |
A.M.Hassell,
G.An,
R.K.Bledsoe,
J.M.Bynum,
H.L.Carter,
S.J.Deng,
R.T.Gampe,
T.E.Grisard,
K.P.Madauss,
R.T.Nolte,
W.J.Rocque,
L.Wang,
K.L.Weaver,
S.P.Williams,
G.B.Wisely,
R.Xu,
and
L.M.Shewchuk
(2007).
Crystallization of protein-ligand complexes.
|
| |
Acta Crystallogr D Biol Crystallogr,
63,
72-79.
|
 |
|
|
|
|
 |
E.A.Ortlund,
J.T.Bridgham,
M.R.Redinbo,
and
J.W.Thornton
(2007).
Crystal structure of an ancient protein: evolution by conformational epistasis.
|
| |
Science,
317,
1544-1548.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.P.Madauss,
E.L.Stewart,
and
S.P.Williams
(2007).
The evolution of progesterone receptor ligands.
|
| |
Med Res Rev,
27,
374-400.
|
 |
|
|
|
|
 |
L.Pujo,
J.Fagart,
F.Gary,
D.T.Papadimitriou,
A.Claës,
X.Jeunemaître,
and
M.C.Zennaro
(2007).
Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism.
|
| |
Hum Mutat,
28,
33-40.
|
 |
|
|
|
|
 |
M.E.Baker,
C.Chandsawangbhuwana,
and
N.Ollikainen
(2007).
Structural analysis of the evolution of steroid specificity in the mineralocorticoid and glucocorticoid receptors.
|
| |
BMC Evol Biol,
7,
24.
|
 |
|
|
|
|
 |
S.K.Panigrahi,
and
G.R.Desiraju
(2007).
Strong and weak hydrogen bonds in the protein-ligand interface.
|
| |
Proteins,
67,
128-141.
|
 |
|
|
|
|
 |
S.Viengchareun,
D.Le Menuet,
L.Martinerie,
M.Munier,
L.Pascual-Le Tallec,
and
M.Lombès
(2007).
The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology.
|
| |
Nucl Recept Signal,
5,
e012.
|
 |
|
|
|
|
 |
J.T.Moore,
J.L.Collins,
and
K.H.Pearce
(2006).
The nuclear receptor superfamily and drug discovery.
|
| |
ChemMedChem,
1,
504-523.
|
 |
|
|
|
|
 |
O.Skøtt,
T.R.Uhrenholt,
J.Schjerning,
P.B.Hansen,
L.E.Rasmussen,
and
B.L.Jensen
(2006).
Rapid actions of aldosterone in vascular health and disease--friend or foe?
|
| |
Pharmacol Ther,
111,
495-507.
|
 |
|
|
|
|
 |
P.Fuller
(2006).
The aldosterone receptor--new insights?
|
| |
Expert Opin Investig Drugs,
15,
201-203.
|
 |
|
|
|
|
 |
S.Inaba,
and
I.Miyamori
(2006).
[Hypertension due to mutation of mineralocorticoid receptors]
|
| |
Nippon Naika Gakkai Zasshi,
95,
677-682.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |